ImmunoGen Inc.

5.85+0.0100+0.17%Vol 1.63M1Y Perf -25.70%
Jan 20th, 2022 11:26 DELAYED
BID5.84 ASK5.85
Open5.95 Previous Close5.84
Pre-Market- After-Market-
 - -%  - -
Target Price
9.30 
Analyst Rating
Moderate Buy 1.86
Potential %
58.16 
Finscreener Ranking
★★     45.39
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
     39.74
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★     43.94
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
18.34 
Earnings Rating
Strong Buy
Market Cap1.19B 
Earnings Date
11th Feb 2022
Alpha0.03 Standard Deviation0.21
Beta1.25 

Today's Price Range

5.836.00

52W Range

4.7210.88

5 Year PE Ratio Range

-4.00-4.90

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-9.60%
1 Month
-15.73%
3 Months
0.52%
6 Months
2.46%
1 Year
-25.70%
3 Years
14.51%
5 Years
140.33%
10 Years
-56.90%

TickerPriceChg.Chg.%
IMGN5.850.01000.17
AAPL169.293.06001.84
GOOG2 750.5637.52001.38
MSFT310.637.30002.41
XOM73.830.72000.98
WFC55.990.42000.76
JNJ167.651.07000.64
FB325.015.42001.70
GE101.120.50000.50
JPM150.141.21000.81
Financial StrengthValueIndustryS&P 500US Markets
2.30
2.20
0.17
0.25
-3.20
Leverage Ratio 3.90
ProfitabilityValueIndustryS&P 500US Markets
46.40
-42.30
-40.70
-118.50
-55.41
RevenueValueIndustryS&P 500US Markets
41.86M
0.19
38.61
15.83
Earnings HistoryEstimateReportedSurprise %
Q03 2021-0.19-0.185.26
Q02 2021-0.18-0.1516.67
Q01 2021-0.19-0.1710.53
Q04 2020-0.040.16500.00
Q03 2020-0.20-0.1335.00
Q02 2020-0.18-0.1422.22
Q01 2020-0.15-0.17-13.33
Q04 2019-0.050.03160.00
Earnings Per EndEstimateRevision %Trend
12/2021 QR-0.1821.74Positive
12/2021 FY-0.695.48Positive
3/2022 QR-0.23-9.52Negative
12/2022 FY-0.95-11.76Negative
Next Report Date11th Feb 2022
Estimated EPS Next Report-0.18
Estimates Count7
EPS Growth Next 5 Years %-
Volume Overview
Volume1.63M
Shares Outstanding202.62M
Shares Float197.21M
Trades Count7.37K
Dollar Volume9.78M
Avg. Volume2.17M
Avg. Weekly Volume2.36M
Avg. Monthly Volume2.13M
Avg. Quarterly Volume4.09M

ImmunoGen Inc. (NASDAQ: IMGN) stock closed at 5.84 per share at the end of the most recent trading day (a -1.35% change compared to the prior day closing price) with a volume of 2.08M shares and market capitalization of 1.19B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 75 people. ImmunoGen Inc. CEO is Mark J. Enyedy.

The one-year performance of ImmunoGen Inc. stock is -25.7%, while year-to-date (YTD) performance is -21.29%. IMGN stock has a five-year performance of 140.33%. Its 52-week range is between 4.72 and 10.88, which gives IMGN stock a 52-week price range ratio of 18.34%

ImmunoGen Inc. currently has a PE ratio of -20.90, a price-to-book (PB) ratio of 18.53, a price-to-sale (PS) ratio of 34.12, a price to cashflow ratio of 141.00, a PEG ratio of 2.32, a ROA of -26.12%, a ROC of -138.09% and a ROE of -407.14%. The company’s profit margin is -55.41%, its EBITDA margin is -40.70%, and its revenue ttm is $41.86 Million , which makes it $0.19 revenue per share.

Of the last four earnings reports from ImmunoGen Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.18 for the next earnings report. ImmunoGen Inc.’s next earnings report date is 11th Feb 2022.

The consensus rating of Wall Street analysts for ImmunoGen Inc. is Moderate Buy (1.86), with a target price of $9.3, which is +58.16% compared to the current price. The earnings rating for ImmunoGen Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

ImmunoGen Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

ImmunoGen Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 24.96, ATR14 : 0.41, CCI20 : -212.68, Chaikin Money Flow : -0.07, MACD : -0.11, Money Flow Index : 20.90, ROC : -21.29, RSI : 34.72, STOCH (14,3) : 1.03, STOCH RSI : 0.00, UO : 35.47, Williams %R : -98.97), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of ImmunoGen Inc. in the last 12-months were: Dean Jonathan Mitchell (Option Excercise at a value of $321 400)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
4 (57.14 %)
4 (57.14 %)
3 (42.86 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
3 (42.86 %)
3 (42.86 %)
4 (57.14 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
1.86
Moderate Buy
1.86
Moderate Buy
2.14

ImmunoGen Inc.

Immunogen Inc is a clinical-stage biotechnology company from the United States. Its focus is antibody-drug conjugate, or ADC, technology, which uses an antibody that fixes on a target (its antigen) found on tumor cells to deliver a specific cancer-killing agent. The technology is used in Kadcyla (ado-trastuzumab emtansine)--a registered trademark of Genentech, a member of the Roche Group--to kill solid tumors. Companies such as Amgen, Genentech/Roche, Lilly, Novartis, Sanofi, and Takeda have licensed limited rights to use the ADC technology in their therapies.

CEO: Mark J. Enyedy

Telephone: +1 781 895-0600

Address: 830 Winter Street, Waltham 02451, MA, US

Number of employees: 75

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

100%0%

Bearish Bullish

73%27%

Bearish Bullish

58%42%

News

Stocktwits